News & Trends - Pharmaceuticals

AbbVie finalises Allergan acquisition

Health Industry Hub | May 13, 2020 |
[Total: 1    Average: 4/5]

AbbVie completed its acquisition of Allergan following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

“We are pleased to reach this important milestone” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our company. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us.”

Locally, the changes to AbbVie and Allergan organisations will be determined and implemented in the near future.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Well-Positioned for Long-Term Growth

The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in Immunology, with Humira, and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta.

Allergan provides new growth opportunities in Neuroscience, with Botox Therapeutics, Vraylar and Ubrelvy and a global aesthetics business, with leading brands including Botox and Juvederm. 

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.

This diversified on-market portfolio will drive the existing AbbVie growth platform (ex-Humira) to approximately $30 billion in revenues in full year 2020, with combined revenues of approximately $50 billion. It also positions the company for enhanced long-term growth potential.

Additionally, in connection with the closing of the transaction, the AbbVie Board of Directors has elected Thomas C. Freyman, retired Executive Vice President and Chief Financial Officer, Abbott, to join the AbbVie board. Mr. Freyman recently served on the Allergan Board of Directors.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - COVID-19 wiping out hard-won gains by women in STEM

COVID-19 wiping out hard-won gains by women in STEM

Health Industry Hub | June 1, 2020 |

Hard-won gains for women’s advancement in the science, technology, engineering and maths (STEM) workforce are now at risk of a […]

More


News & Trends - Medical Technology

MedTech News - New agreement to end public hospitals' “harvesting” of privately insured patients

New agreement to end public hospital “harvesting” of privately insured patients

Health Industry Hub | June 1, 2020 |

MedTech News: The new National Health Reform Agreement has the potential to end the practice of public hospitals “harvesting” privately […]

More


News & Trends - Pharmaceuticals

Pharma News - GSK's targeted therapy for asthma gains PBS listing for self-administration delivery

GSK’s targeted therapy for asthma gains PBS listing for self-administration delivery

Health Industry Hub | June 1, 2020 |

Pharma News: From 1 June 2020, GSK Australia’s new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for […]

More


News & Trends - Pharmaceuticals

Pharma News - Major changes to opioid PBS listings effective 1 June

Major changes to opioid PBS listings effective 1 June

Health Industry Hub | June 1, 2020 |

Commencing 1 June 2020, the Pharmaceutical Benefits Scheme (PBS) listings for opioid medicines will change including Tramal (tramadol) and Panadeine […]

More